Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial

Published:2018-11-26 Issue:12 Volume:41 Page:1513-1520
ISSN:0160-9289
Container-title:Clinical Cardiology
language:en
Short-container-title:Clin Cardiol

Author:

Koskinas Konstantinos C.¹^ORCID,Windecker Stephan¹,Buhayer Aliki²,Gencer Baris³,Pedrazzini Giovanni⁴,Mueller Christian⁵,Cook Stephan⁶,Muller Olivier⁷,Matter Christian M.⁸,Räber Lorenz¹,Heg Dik⁹,Mach François³,

Affiliation:

1. Department of Cardiology; Bern University Hospital; Bern Switzerland

2. PRISM Scientific Sàrl; Switzerland

3. Department of Cardiology; Geneva University Hospital; Geneva Switzerland

4. Cardiocentro; Lugano Switzerland

5. Department of Cardiology and Cardiovascular Research Institute Basel; University Hospital Basel; Basel Switzerland

6. Department of Cardiology; Fribourg Hospital and University; Fribourg Switzerland

7. Service of Cardiology; Lausanne University Hospital; Lausanne Switzerland

8. Department of Cardiology, University Heart Center; University Hospital Zurich; Zurich Switzerland

9. CTU Bern; University of Bern; Bern Switzerland

Funder

Amgen

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/clc.23112/fullpdf

Reference43 articles.

1. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC);Roffi;Eur Heart J,2016

2. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials;Koskinas;Eur Heart J,2018

3. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes. Results from the PROVE IT-TIMI 22 trial;Ray;J Am Coll Cardiol,2005

4. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes;Schwartz;JAMA,2001

5. Effect of loading dose of atorvastatin prior to planned percutaneous coronary intervention on major adverse cardiovascular events in acute coronary syndrome: the SECURE-PCI randomized clinical trial;Berwanger;JAMA,2018

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early Management of Blood Lipid Levels with Non-Statin Lipid-Lowering Drugs in Acute Coronary Syndrome: A Mini Review;Cardiovascular Drugs and Therapy;2024-06-29

2. Recurrent Acute Coronary Syndrome in Young Man with Familial Hypercholesterolemia: Efficacy of Evolocumab Add-On Treatment Demonstrated via Serial Coronary Angiography;Biomedicines;2024-05-17

3. Extremely high-risk patients with acute coronary syndrome: How “extreme” should lipid-lowering therapy be if the LDL-C target <40 mg/dl is considered?;Kardiologia Polska;2023-10-31

4. The Anti-Thrombotic Effects of PCSK9 Inhibitors;Pharmaceuticals;2023-08-22

5. Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9;Pharmacological Research;2022-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3